Page 1141 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 63 Myelodysplastic Syndromes and Myeloproliferative Neoplasms in Children 1004.e3

90. Willasch AM, Kreyenberg H, Shayegi N, et al: Monitoring of hema- 109. Yakoub-Agha I, de La Salmoniere P, Ribaud P, et al: Allogeneic bone
topoietic chimerism after transplantation for pediatric myelodysplastic marrow transplantation for therapy-related myelodysplastic syndrome
syndrome: real-time or conventional short tandem repeat PCR in and acute myeloid leukemia: a long-term study of 70 patients-report
peripheral blood or bone marrow? Biol Blood Marrow Transplant 20: of the French Society of Bone Marrow Transplantation. J Clin Oncol
1918, 2014. 18:963, 2000.
91. Greenberg P, Cox C, LeBeau MM, et al: International scoring system 110. Barnard DR, Lange B, Alonzo TA, et al: Acute myeloid leukemia and
for evaluating prognosis in myelodysplastic syndromes [see comments]. myelodysplastic syndrome in children treated for cancer: comparison
Blood 89:2079, 1997. with primary presentation. Blood 100:427, 2002.
92. Malcovati L, Germing U, Kuendgen A, et al: Time-dependent prog- 111. Emanuel PD: Myelodysplasia and myeloproliferative disorders in child-
nostic scoring system for predicting survival and leukemic evolution in hood: an update. Br J Haematol 105:852, 1999.
myelodysplastic syndromes. J Clin Oncol 25:3503, 2007. 112. Niemeyer CM, Loh ML, Cseh A, et al: Criteria for evaluating response
93. Porta MGD, Tuechler H, Malcovati L, et al: Validation of WHO and outcome in clinical trials for children with juvenile myelomonocytic
classification-based prognostic scoring system (WPSS) for myelodysplas- leukemia. Haematologoca 100:17, 2015.
tic syndromes and comparison with the revised International Prognostic 113. Hasle H: Myelodysplastic and myeloproliferative disorders in children.
Scoring System (IPSS-R). A study of the International Working Group Curr Opin Pediatr 19:1, 2007.
for Prognosis in myelodysplasia (IWG-PM). Leukemia 29:1502, 2015. 114. Hays T, Humbert JR, Peakman DC, et al: Missing Y chromosome in
94. Hasle H, Baumann I, Bergstrasser E, et al: The International Prognostic juvenile chronic myelogenous leukemia. Humangenetik 29:259, 1975.
Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) 115. Inoue S, Ravindranath Y, Thompson RI, et al: Cytogenetics of juvenile
and juvenile myelomonocytic leukemia (JMML). Leukemia 18:2008, type chronic granulocytic leukemia. Cancer 39:2017, 1977.
2004. 116. Inoue S, Shibata T, Ravindranath Y, et al: Clonal origin of erythroid
95. Harrison CN, Vaughan G, Devereux S, et al: Outcome of secondary cells in juvenile chronic myelogenous leukemia [letter]. Blood 69:975,
myeloid malignancy in Hodgkin’s disease: the BNLI experience. Eur J 1987.
Haematol 61:109, 1998. 117. Brodeur GM, Dow LW, Williams DL: Cytogenetic features of juvenile
96. Harrison CN, Gregory W, Hudson GV, et al: High-dose BEAM chronic myelogenous leukemia. Blood 53:812, 1979.
chemotherapy with autologous haemopoietic stem cell transplantation 118. Amenomori T, Tomonaga M, Yoshida Y, et al: Cytogenetic evidence
for Hodgkin’s disease is unlikely to be associated with a major increased for partially committed myeloid progenitor cell origin of chronic
risk of secondary MDS/AML. Br J Cancer 81:476, 1999. myelomonocytic leukaemia and juvenile chronic myeloid leukaemia:
97. Milligan DW, Ruiz De Elvira MC, Kolb HJ, et al: Secondary leukaemia both granulocyte-macrophage precursors and erythroid precursors carry
and myelodysplasia after autografting for lymphoma: results from the identical marker chromosome. Br J Haematol 64:539, 1986.
EBMT. EBMT Lymphoma and Late Effects Working Parties. Euro- 119. Busque L, Gilliland DG, Prchal JT, et al: Clonality in juvenile chronic
pean Group for Blood and Marrow Transplantation. Br J Haematol myelogenous leukemia. Blood 85:21, 1995.
106:1020, 1999. 120. Emanuel PD, Snyder RC, Wiley T, et al: Inhibition of juvenile
98. Laver JH, Yusuf U, Cantu ES, et al: Transient therapy-related myelo- myelomonocytic leukemia cell growth in vitro by farnesyltransferase
dysplastic syndrome associated with monosomy 7 and 11q23 transloca- inhibitors. Blood 95:639, 2000.
tion. Leukemia 11:448, 1997. 121. Cooper LJ, Shannon KM, Loken MR, et al: Evidence that juvenile
99. Thirman MJ, Larson RA: Therapy-related myeloid leukemia. Hematol myelomonocytic leukemia can arise from a pluripotential stem cell.
Oncol Clin North Am 10:293, 1996. Blood 96:2310, 2000.
100. Kushner BH, Heller G, Cheung NK, et al: High risk of leukemia after 122. Lapidot T, Grunberger T, Vormoor J, et al: Identification of human
short-term dose-intensive chemotherapy in young patients with solid juvenile chronic myelogenous leukemia stem cells capable of initiating
tumors. J Clin Oncol 16:3016, 1998. the disease in primary and secondary SCID mice. Blood 88:2655,
101. Schneider DT, Hilgenfeld E, Schwabe D, et al: Acute myelogenous 1996.
leukemia after treatment for malignant germ cell tumors in children. 123. Stieglitz E, Troup CB, Gelston LC, et al: Subclonal mutations in
J Clin Oncol 17:3226, 1999. SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.
102. Travis LB, Curtis RE, Storm H, et al: Risk of second malignant neo- Blood 125:516, 2015.
plasms among long-term survivors of testicular cancer [see comments]. 124. Shannon KM, O’Connell P, Martin GA, et al: Loss of the normal NF1
J Natl Cancer Inst 89:1429, 1997. allele from the bone marrow of children with type 1 neurofibromatosis
103. Dunst J, Ahrens S, Paulussen M, et al: Second malignancies after treat- and malignant myeloid disorders [see comments]. N Engl J Med
ment for Ewing’s sarcoma: a report of the CESS-studies. Int J Radiat 330:597, 1994.
Oncol Biol Phys 42:379, 1998. 125. Miyauchi J, Asada M, Sasaki M, et al: Mutations of the N-ras gene in
104. Burdach S, van Kaick B, Laws HJ, et al: Allogeneic and autologous juvenile chronic myelogenous leukemia. Blood 83:2248, 1994.
stem-cell transplantation in advanced Ewing tumors. An update after 126. Largaespada DA, Brannan CI, Jenkins NA, et al: Nf1 deficiency
long-term follow-up from two centers of the European Intergroup causes Ras-mediated granulocyte/macrophage colony stimulating factor
study EICESS. Stem-Cell Transplant Programs at Dusseldorf University hypersensitivity and chronic myeloid leukaemia. Nat Genet 12:137,
Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. 1996.
Ann Oncol 11:1451, 2000. 127. Bollag G, Clapp DW, Shih S, et al: Loss of NF1 results in activa-
105. Rodriguez-Galindo C, Poquette CA, Marina NM, et al: Hematologic tion of the Ras signaling pathway and leads to aberrant growth in
abnormalities and acute myeloid leukemia in children and adolescents haematopoietic cells. Nat Genet 12:144, 1996.
administered intensified chemotherapy for the Ewing sarcoma family 128. Tartaglia M, Niemeyer CM, Fragale A, et al: Somatic mutations in
of tumors. J Pediatr Hematol Oncol 22:321, 2000. PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic
106. Tsurusawa M, Manabe A, Hayashi Y, et al: Therapy-related myelodys- syndromes and acute myeloid leukemia. Nat Genet 34:148, 2003.
plastic syndrome in childhood: a retrospective study of 36 patients in 129. Loh ML, Sakai DS, Flotho C, et al: Mutations in CBL occur frequently
Japan. Leuk Res 29:625, 2005. in juvenile myelomonocytic leukemia. Blood 114:1859, 2009.
107. Bhatia S, Krailo MD, Chen Z, et al: Therapy-related myelodysplasia 130. Niemeyer CM, Kang MW, Shin DH, et al: Germine CBL mutations
and acute myeloid leukemia after Ewing sarcoma and primitive neu- cause developmental abnormalities and predispose to juvenile myelo-
roectodermal tumor of bone: a report from the Children’s Oncology monocytic leukemia. Nat Genet 42:794, 2010.
Group. Blood 109:46, 2007. 131. Muramatsu H, Makishima H, Jankowska AM, et al: Mutations of an
108. Tebbi CK, London WB, Friedman D, et al: Dexrazoxane-associated E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in
risk for acute myeloid leukemia/myelodysplastic syndrome and other juvenile myelomonocytic leukemia. Blood 115:1969, 2010.
secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol 132. Niihori T, Aoki Y, Narumi Y, et al: Germline KRAS and BRAF muta-
25:493, 2007. tions in cardio-facio-cutaneous syndrome. Nat Genet 38:294, 2006.